Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

被引：1
|
作者：
Chica-Parrado, Maria del Rosario
Kin, Gun Min
Lin, Chang-Ching
Lee, Kyung-Min
Napolitano, Fabiana
Ye, Dan
Bikorimana, Emmanuel
Mendirata, Saurabh
Hanker, Ariella
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5483
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
    Leon-Ferre, Roberto A.
    Carter, Jodi M.
    Zahrieh, David M.
    Hillman, David W.
    Chumsri, Saranya
    Ma, Yaohua
    Kachergus, Jennifer M.
    Wang, Xue
    Boughey, Judy C.
    Liu, Minetta C.
    Ingle, James N.
    Kalari, Krishna R.
    Bisneto, Jose C. Villasboas
    Couch, Fergus J.
    Thompson, E. Aubrey
    Goetz, Matthew P.
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
    Teo, Zhi Ling
    Versaci, Stephanie
    Dushyanthen, Sathana
    Caramia, Franco
    Savas, Peter
    Mintoff, Chris P.
    Zethoven, Magnus
    Virassamy, Balaji
    Luen, Stephen J.
    McArthur, Grant A.
    Phillips, Wayne A.
    Darcy, Phillip K.
    Loi, Sherene
    CANCER RESEARCH, 2017, 77 (22) : 6340 - 6352
  • [23] Deguelin selectively inhibits proliferation of luminal androgen receptor (LAR) triple-negative breast cancer cells
    Robles, Andrew J.
    Cai, Shengxin
    Cichewicz, Robert H.
    Mooberry, Susan L.
    CANCER RESEARCH, 2015, 75
  • [24] Investigating anti-tumor immunity with CDK4/6 inhibition in triple negative breast cancer.
    Guo, Qiuchen
    Spasic, Milos
    Goreczny, Gregory
    Maynard, Adam
    McAllister, Sandra
    CANCER RESEARCH, 2021, 81 (13)
  • [25] CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    MEDCOMM, 2021, 2 (04): : 514 - 530
  • [26] CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Goel, Shom
    Tolaney, Sara M.
    LANCET ONCOLOGY, 2019, 20 (11): : 1479 - 1481
  • [27] Palbociclib, a CDK4/6 inhibitor, suppresses proliferation of triple negative breast cancer
    Min, Ahrum
    Kim, Yu Jin
    Hang, Hyemin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, So Hyeon
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Hu, Ye
    Gao, Jiyue
    Wang, Meiling
    Li, Man
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5223 - 5237
  • [29] Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
    Wang, Runtian
    Xu, Kun
    Gao, Fangyan
    Huang, Jinyi
    Guan, Xiaoxiang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [30] Combination of CDK4/6 inhibitors with biguanides for treatment of triple negative breast cancer
    Martinez, Mario Morales
    Gonzalez, Eduardo Mauricio
    Deng, Gang
    Ma, Gaoyuan
    Kim, Hyunsoo
    Stiles, Linsey
    Hamilton, Nalo
    Jung, Michael E.
    Pietras, Richard J.
    Marquez-Garban, Diana C.
    CANCER RESEARCH, 2024, 84 (06)
12345